| Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q3 2024 | 35 | 1,499,957 | BLFS, RVMD, WGS, LAB | 13F-HR | 11/14/2024 | 000091957424006736 |
| Q2 2024 | 38 | 1,309,655 | BLFS, RVMD, SRPT, LAB | RESTATEMENT | 10/18/2024 | 000091957424005948 |
| Q1 2024 | 37 | 1,345,191 | RVMD, LAB, BLFS, SRPT | 13F-HR | 5/15/2024 | 000091957424003198 |
| Q4 2023 | 38 | 1,018,739 | RVMD, BLFS, SRPT, RLAY | 13F-HR | 2/14/2024 | 000091957424001474 |
| Q3 2023 | 40 | 903,526 | SRPT, BLFS, EQRX, GPCR | 13F-HR | 11/14/2023 | 000091957423006405 |
| Q2 2023 | 41 | 1,144,294 | BLFS, SRPT, RLAY, EQRX | 13F-HR | 8/14/2023 | 000091957423004796 |
| Q1 2023 | 41 | 1,213,998 | BLFS, SRPT, RLAY, EQRX | 13F-HR | 5/15/2023 | 000091957423003310 |
| Q4 2022 | 46 | 1,290,660 | SRPT, BLFS, EQRX, ALNY | 13F-HR | 2/14/2023 | 000091957423001552 |
| Q3 2022 | 37 | 1,522,338 | EQRX, BLFS, SRPT, ALNY | 13F-HR | 11/14/2022 | 000091957422006773 |
| Q2 2022 | 40 | 1,182,711 | EQRX, ALNY, BLFS, RLAY | 13F-HR | 8/15/2022 | 000091957422005034 |
| Q1 2022 | 47 | 2,230,233 | BLFS, ALNY, EQRX, FATE | 13F-HR | 5/16/2022 | 000153426122000004 |
| Q4 2021 | 53 | 3,548,006 | BLFS, EQRX, FATE, NVTA | 13F-HR | 2/14/2022 | 000153426122000002 |
| Q3 2021 | 54 | 4,017,507 | NVTA, BLFS, EXAS, PACB | 13F-HR | 11/15/2021 | 000153426121000008 |
| Q2 2021 | 54 | 3,939,403 | NVTA, BLFS, FATE, EXAS | 13F-HR | 8/16/2021 | 000153426121000006 |
| Q1 2021 | 48 | 3,357,621 | NVTA, EXAS, FATE, BLFS | 13F-HR | 5/17/2021 | 000153426121000004 |
| Q4 2020 | 52 | 3,375,426 | NVTA, BLFS, FATE, EXAS | 13F-HR | 2/16/2021 | 000153426121000002 |
| Q3 2020 | 45 | 2,233,335 | NVTA, BLFS, RLAY, BPMC | 13F-HR | 11/16/2020 | 000153426120000014 |
| Q2 2020 | 42 | 1,689,747 | NVTA, BPMC, FATE, SRPT | 13F-HR | 8/14/2020 | 000153426120000012 |
| Q1 2020 | 38 | 942,016 | BPMC, SRPT, ALNY, FATE | 13F-HR | 5/15/2020 | 000153426120000008 |
| Q4 2019 | 32 | 1,087,417 | SRPT, BLUE, CDXS, BPMC | 13F-HR | 2/14/2020 | 000153426120000005 |
| Q3 2019 | 33 | 966,300 | ONCE, NVTA, CDXS, BPMC | RESTATEMENT | 1/3/2020 | 000153426120000001 |
| Q3 2019 | 33 | 999,623 | ONCE, NVTA, SAGE, BPMC | NEW HOLDINGS | 11/12/2019 | 000153426119000012 |
| Q2 2019 | 31 | 1,068,381 | ONCE, NVTA, BPMC, CDXS | 13F-HR | 8/13/2019 | 000153426119000010 |
| Q1 2019 | 29 | 910,374 | ONCE, BPMC, MYOK, SAGE | 13F-HR | 5/15/2019 | 000153426119000008 |
| Q4 2018 | 31 | 584,510 | LOXO, MYOK, BPMC, CDXS | 13F-HR | 2/13/2019 | 000153426119000007 |
| Q3 2018 | 36 | 822,765 | LOXO, BPMC, MYOK, AGIO | 13F-HR | 11/14/2018 | 000117266118002093 |
| Q2 2018 | 35 | 715,025 | FMI, LOXO, BPMC, SAGE | RESTATEMENT | 8/20/2018 | 000117266118001712 |
| Q1 2018 | 31 | 568,612 | LOXO, FMI, SAGE, BPMC | 13F-HR | 5/15/2018 | 000117266118001199 |
| Q4 2017 | 27 | 410,635 | SAGE, FMI, LOXO, BPMC | 13F-HR | 2/14/2018 | 000117266118000559 |
| Q3 2017 | 26 | 354,153 | LOXO, MYOK, ALNY, SGMO | 13F-HR | 11/14/2017 | 000117266117002006 |
| Q2 2017 | 35 | 270,353 | LOXO, SAGE, FMI, BPMC | 13F-HR | 8/14/2017 | 000117266117001658 |
| Q1 2017 | 29 | 169,512 | SAGE, FMI, LOXO, AGIO | 13F-HR | 5/15/2017 | 000117266117001193 |
| Q4 2016 | 25 | 121,078 | SAGE, LOXO, AGIO, FMI | 13F-HR | 2/14/2017 | 000117266117000699 |
| Q3 2016 | 26 | 123,498 | AGIO, SAGE, FMI, EVH | 13F-HR | 11/14/2016 | 000117266116004290 |
| Q2 2016 | 27 | 100,465 | ONCE, AGIO, FMI, GLOBAL BLOOD THERAPEUTICS IN | 13F-HR | 8/15/2016 | 000117266116003861 |
| Q1 2016 | 26 | 87,125 | LOXO, EPZM, FMI, SAGE | 13F-HR | 5/9/2016 | 000117266116003186 |
| Q4 2015 | 31 | 113,179 | BPMC, SAGE, LOXO, CTMX | 13F-HR | 2/8/2016 | 000117266116002454 |